Health Catalyst Divests Vitalware Business for $147 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 04 2026
0mins
Source: Newsfilter
- Strategic Focus: Health Catalyst has signed a definitive agreement to divest its Vitalware business to Med-Metrix for $147 million in cash, which sharpens the company's focus on enhancing health systems' cost, clinical, and consumer performance, and is expected to accelerate its ongoing transformation.
- Increased Financial Flexibility: The transaction is anticipated to strengthen Health Catalyst's balance sheet, providing greater financial flexibility to prioritize investments in core technology and AI, thereby supporting its long-term strategy.
- Debt Repayment Plan: The company plans to use the net proceeds from the divestiture, along with cash on hand, to fully repay approximately $160 million of its senior secured term loan, reducing financial burdens and optimizing its capital structure.
- Vitalware's Market Position: Vitalware, a leading revenue cycle management software provider with approximately $37 million in revenue for fiscal year 2025, will benefit from Med-Metrix's acquisition, which positions it for deeper investment and development opportunities, further solidifying its leadership in the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HCAT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HCAT
Wall Street analysts forecast HCAT stock price to rise
7 Analyst Rating
3 Buy
4 Hold
0 Sell
Moderate Buy
Current: 1.770
Low
2.75
Averages
3.85
High
5.00
Current: 1.770
Low
2.75
Averages
3.85
High
5.00
About HCAT
Health Catalyst, Inc. is a provider of data and analytics technology and services to healthcare organizations. The Company's solution comprises its cloud-based data platform, applications, and expertise. Its segments include Technology and Professional Services. The Technology segment includes its data platform, analytics applications and support services and earns primarily from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees. The Professional Services segment is generally a combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver capabilities to its clients to fully configure and utilize the benefits of its technology offerings. Its clients, which are primarily healthcare providers, use its Solution to manage their data, derive analytical insights to operate their organization, and produce measurable clinical, financial, and operational improvements.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Outset Medical Shares Surge 25.6% on HCA Deal
- Significant Price Surge: Outset Medical's shares soared 25.6% in the last trading session to close at $5.05, with trading volume significantly exceeding normal levels, reflecting investor optimism about the company's future prospects.
- Key Contract Signing: The company entered into a Refresh Amendment to its Purchasing Agreement with HCA Management Services, which will purchase new Tablo Hemodialysis Systems from 2026 to 2028 for an aggregate value of approximately $40 million, providing a stable revenue stream for the company.
- Earnings Report Expectations: Outset Medical is expected to report a quarterly loss of $0.63 per share, representing a year-over-year change of +25%, while revenues are projected at $28.8 million, down 8.3% from the previous year, yet the market remains optimistic about future growth potential.
- Market Performance Analysis: Although the current EPS estimates have remained unchanged over the past 30 days, the stock's price increase is typically correlated with trends in earnings estimates, prompting investors to monitor Outset Medical's future earnings trends to assess the sustainability of its stock price increase.
See More
Analysis of Falling Shares of Health Catalyst and Paycom
- Market Volatility Impact: Health Catalyst (HCAT) shares fell 3.6% and Paycom (PAYC) dropped 3.5% as investors rotated from high-multiple growth stocks to cyclicals, indicating a cautious market sentiment towards tech stocks amid rising inflation data.
- Inflation Data Shock: May import prices rose by 1.9%, significantly above the 1.1% forecast, with an annual increase of 6.7%, the largest since August 2022, exacerbating concerns about future interest rate hikes and impacting software company valuations.
- AI Bubble Risk: A Bank of America fund manager survey revealed that 28% of respondents view the AI bubble as the second-largest tail risk, prompting portfolio managers to reduce allocations to tech stocks, which adds further pressure on companies like Health Catalyst and Paycom.
- Poor Long-term Performance: Health Catalyst has declined 23% year-to-date, trading at $1.76, which is 57.1% below its 52-week high of $4.09, reflecting diminished investor confidence in its future cash flows and a broader pessimistic sentiment towards the software sector.
See More
Health Catalyst to Participate in Healthcare Disruptors Conference
- Executive Participation: Health Catalyst's senior management will participate in the Truist Securities Healthcare Disruptors & Digital Health Conference, with CEO Ben Albert leading a panel discussion on 'AI ROI in Healthcare: Real vs Hype' on June 24, 2026, at 3:30 PM, showcasing the company's leadership in the industry.
- Technology-Driven Outcomes: Leveraging proprietary AI-driven technology, Health Catalyst has documented $2.8 billion in outcomes, assisting health systems in achieving measurable improvements across cost, clinical, and consumer performance, thereby solidifying its competitive edge in the market.
- Industry Influence: By engaging in significant industry conferences, Health Catalyst not only demonstrates its expertise in healthcare intelligence but also provides attendees with profound insights on leveraging AI technology to enhance healthcare efficiency, driving industry innovation.
- Strengthening Investor Relations: This conference offers Health Catalyst an opportunity to interact with investors and industry leaders, further enhancing its influence in the healthcare sector and laying the groundwork for future strategic collaborations.
See More
Veru Shares Surge 88% on Novo Nordisk Collaboration
- Veru Stock Surge: Shares of Veru Inc. (VERU) soared 88% on Thursday following a clinical supply agreement with Novo Nordisk, which involves a Phase 2b trial of its lead drug Enobosarm, potentially enhancing the company's market position in obesity treatment significantly.
- Clinical Trial Details: The PLATEAU trial will assess the effects of Enobosarm on total body weight and bone density in approximately 200 older patients with obesity, with Novo Nordisk providing Wegovy at no cost to ensure the trial's success.
- Health Catalyst Strategic Shift: Health Catalyst Inc. (HCAT) closed at $1.94, up 45.86%, as its subsidiary Vitalware was acquired by Med-Metrix, marking a new phase for the company and expected to strengthen its competitive edge in healthcare data analytics.
- Absci Clinical Progress: Absci Corp. (ABSI) shares rose 23.57% as the company advances its AI-designed antibody ABS-201 in clinical trials, with preliminary safety data expected in 2026, which could propel its growth in the biopharmaceutical sector.
See More
Med-Metrix Acquires Vitalware to Enhance Technology Platform
- Acquisition Agreement: Med-Metrix has entered into a definitive agreement to acquire Vitalware from Health Catalyst, which is expected to enhance Med-Metrix's technology platform and improve reimbursement accuracy and net revenue yield for its clients.
- Integration Benefits: The leadership team and employees of Vitalware will be integrated into Med-Metrix's operations, enhancing the company's ability to deliver end-to-end revenue cycle management solutions by combining differentiated technology with operational expertise.
- Industry Impact: Founded in 2011, Vitalware's cloud-based solutions have been widely adopted across hospitals and health systems, improving visibility and continuity in billing and coding processes, thereby enhancing client satisfaction.
- Financial Outcome Expectations: Med-Metrix executives highlighted that the acquisition will help providers identify revenue leakage, strengthen compliance, and optimize net patient revenue, further enhancing the company's competitive position in the healthcare revenue cycle management sector.
See More
Med-Metrix Acquires Vitalware to Enhance Revenue Management
- Acquisition Overview: Med-Metrix has entered into a definitive agreement to acquire Vitalware, a leader in revenue workflow and analytics software owned by Health Catalyst, which is expected to significantly enhance Med-Metrix's mid-revenue cycle capabilities and improve net revenue yield for its clients.
- Technological Integration Benefits: Vitalware's cloud-based solutions excel in chargemaster management, revenue integrity, and coding workflows, and by integrating this technology, Med-Metrix will better support its expanding health system client base in identifying revenue leakage and optimizing net patient revenue.
- Leadership Team Integration: Following the acquisition, Vitalware's leadership team and employees will be integrated into Med-Metrix's operations, which will not only enhance the company's operational capabilities but also improve its ability to deliver end-to-end solutions, driving further business growth.
- Strategic Investment Context: Supported by Harvest Partners and A&M Capital Partners, this acquisition reflects confidence in Med-Metrix's future growth strategy, with Vitalware's addition providing stronger market competitiveness and technological support to aid its continued expansion in the healthcare services sector.
See More
Outset Medical Shares Surge 25.6% on HCA Deal
- Significant Price Surge: Outset Medical's shares soared 25.6% in the last trading session to close at $5.05, with trading volume significantly exceeding normal levels, reflecting investor optimism about the company's future prospects.
- Key Contract Signing: The company entered into a Refresh Amendment to its Purchasing Agreement with HCA Management Services, which will purchase new Tablo Hemodialysis Systems from 2026 to 2028 for an aggregate value of approximately $40 million, providing a stable revenue stream for the company.
- Earnings Report Expectations: Outset Medical is expected to report a quarterly loss of $0.63 per share, representing a year-over-year change of +25%, while revenues are projected at $28.8 million, down 8.3% from the previous year, yet the market remains optimistic about future growth potential.
- Market Performance Analysis: Although the current EPS estimates have remained unchanged over the past 30 days, the stock's price increase is typically correlated with trends in earnings estimates, prompting investors to monitor Outset Medical's future earnings trends to assess the sustainability of its stock price increase.
See More
Analysis of Falling Shares of Health Catalyst and Paycom
- Market Volatility Impact: Health Catalyst (HCAT) shares fell 3.6% and Paycom (PAYC) dropped 3.5% as investors rotated from high-multiple growth stocks to cyclicals, indicating a cautious market sentiment towards tech stocks amid rising inflation data.
- Inflation Data Shock: May import prices rose by 1.9%, significantly above the 1.1% forecast, with an annual increase of 6.7%, the largest since August 2022, exacerbating concerns about future interest rate hikes and impacting software company valuations.
- AI Bubble Risk: A Bank of America fund manager survey revealed that 28% of respondents view the AI bubble as the second-largest tail risk, prompting portfolio managers to reduce allocations to tech stocks, which adds further pressure on companies like Health Catalyst and Paycom.
- Poor Long-term Performance: Health Catalyst has declined 23% year-to-date, trading at $1.76, which is 57.1% below its 52-week high of $4.09, reflecting diminished investor confidence in its future cash flows and a broader pessimistic sentiment towards the software sector.
See More
Health Catalyst to Participate in Healthcare Disruptors Conference
- Executive Participation: Health Catalyst's senior management will participate in the Truist Securities Healthcare Disruptors & Digital Health Conference, with CEO Ben Albert leading a panel discussion on 'AI ROI in Healthcare: Real vs Hype' on June 24, 2026, at 3:30 PM, showcasing the company's leadership in the industry.
- Technology-Driven Outcomes: Leveraging proprietary AI-driven technology, Health Catalyst has documented $2.8 billion in outcomes, assisting health systems in achieving measurable improvements across cost, clinical, and consumer performance, thereby solidifying its competitive edge in the market.
- Industry Influence: By engaging in significant industry conferences, Health Catalyst not only demonstrates its expertise in healthcare intelligence but also provides attendees with profound insights on leveraging AI technology to enhance healthcare efficiency, driving industry innovation.
- Strengthening Investor Relations: This conference offers Health Catalyst an opportunity to interact with investors and industry leaders, further enhancing its influence in the healthcare sector and laying the groundwork for future strategic collaborations.
See More
Veru Shares Surge 88% on Novo Nordisk Collaboration
- Veru Stock Surge: Shares of Veru Inc. (VERU) soared 88% on Thursday following a clinical supply agreement with Novo Nordisk, which involves a Phase 2b trial of its lead drug Enobosarm, potentially enhancing the company's market position in obesity treatment significantly.
- Clinical Trial Details: The PLATEAU trial will assess the effects of Enobosarm on total body weight and bone density in approximately 200 older patients with obesity, with Novo Nordisk providing Wegovy at no cost to ensure the trial's success.
- Health Catalyst Strategic Shift: Health Catalyst Inc. (HCAT) closed at $1.94, up 45.86%, as its subsidiary Vitalware was acquired by Med-Metrix, marking a new phase for the company and expected to strengthen its competitive edge in healthcare data analytics.
- Absci Clinical Progress: Absci Corp. (ABSI) shares rose 23.57% as the company advances its AI-designed antibody ABS-201 in clinical trials, with preliminary safety data expected in 2026, which could propel its growth in the biopharmaceutical sector.
See More
Med-Metrix Acquires Vitalware to Enhance Technology Platform
- Acquisition Agreement: Med-Metrix has entered into a definitive agreement to acquire Vitalware from Health Catalyst, which is expected to enhance Med-Metrix's technology platform and improve reimbursement accuracy and net revenue yield for its clients.
- Integration Benefits: The leadership team and employees of Vitalware will be integrated into Med-Metrix's operations, enhancing the company's ability to deliver end-to-end revenue cycle management solutions by combining differentiated technology with operational expertise.
- Industry Impact: Founded in 2011, Vitalware's cloud-based solutions have been widely adopted across hospitals and health systems, improving visibility and continuity in billing and coding processes, thereby enhancing client satisfaction.
- Financial Outcome Expectations: Med-Metrix executives highlighted that the acquisition will help providers identify revenue leakage, strengthen compliance, and optimize net patient revenue, further enhancing the company's competitive position in the healthcare revenue cycle management sector.
See More
Med-Metrix Acquires Vitalware to Enhance Revenue Management
- Acquisition Overview: Med-Metrix has entered into a definitive agreement to acquire Vitalware, a leader in revenue workflow and analytics software owned by Health Catalyst, which is expected to significantly enhance Med-Metrix's mid-revenue cycle capabilities and improve net revenue yield for its clients.
- Technological Integration Benefits: Vitalware's cloud-based solutions excel in chargemaster management, revenue integrity, and coding workflows, and by integrating this technology, Med-Metrix will better support its expanding health system client base in identifying revenue leakage and optimizing net patient revenue.
- Leadership Team Integration: Following the acquisition, Vitalware's leadership team and employees will be integrated into Med-Metrix's operations, which will not only enhance the company's operational capabilities but also improve its ability to deliver end-to-end solutions, driving further business growth.
- Strategic Investment Context: Supported by Harvest Partners and A&M Capital Partners, this acquisition reflects confidence in Med-Metrix's future growth strategy, with Vitalware's addition providing stronger market competitiveness and technological support to aid its continued expansion in the healthcare services sector.
See More
